Lexeo Therapeutics, Inc. Common Stock (LXEO) vs X4 Pharmaceuticals, Inc. (XFOR)

A side-by-side comparison of Lexeo Therapeutics, Inc. Common Stock and X4 Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Lexeo Therapeutics, Inc. Common Stock logo
LXEO
Lexeo Therapeutics, Inc. Common Stock
$259M
$3.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
X4 Pharmaceuticals, Inc. logo
XFOR
X4 Pharmaceuticals, Inc.
$261M
$2.77HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — LXEO vs XFOR

growth of $100 · dividends reinvested · last 3y
LXEO -66.1% (-30.3%/yr)XFOR -89.8% (-53.2%/yr)LXEO compounded faster over this window
050100150200Start $100202420252026$34$10
LXEO XFOR

LXEO vs XFOR: by the numbers

  • •XFOR is the larger company ($261M vs $259M market cap).
  • •Both run net losses; LXEO's is the smaller (0.00% vs -568.80% net margin).

Metrics side by side

Valuation

MetricLXEOXFOR
P/S ratioN/A16.49
P/B ratio1.101.68

Profitability

MetricLXEOXFOR
Gross margin0.00%81.22%
Operating margin0.00%-247.44%
Net margin0.00%-568.80%
ROE-37.12%-57.98%
ROIC-39.76%-37.61%

Growth (annualized)

MetricLXEOXFOR
Total return CAGR (5Y)N/A-55.06%

Go deeper

Full LXEO analysisFull XFOR analysisInteractive comparison tool

Dig into the metrics

Lexeo Therapeutics, Inc. Common Stock ROEX4 Pharmaceuticals ROELexeo Therapeutics, Inc. Common Stock operating marginX4 Pharmaceuticals operating marginLexeo Therapeutics, Inc. Common Stock revenue growthX4 Pharmaceuticals revenue growthLexeo Therapeutics, Inc. Common Stock free cash flowX4 Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.